Japanese study of Linagliptin for type 2 diabetes patients with NAFLD in Kagoshima
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-UMIN000014864
- Lead Sponsor
- Japan society of Patient Reported Outcome
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 48
Not provided
Person who correspond to any of following will be excluded; Exclusion Criteria; 1.Type1 diabetes or secondary diabetes 2.Current use of warfarin potassium 3.Hepatitis B surface antigen positive or HCV antibody positive 4.Has severe injury, severe infection or an operation scheduled within one year 5.MI, AP, or CI in 12 weeks before obtaining informed consent 6.Atrial fibrillation or frequent ventricular ectopy 7.Moderate or greater cardiac insufficiency ,stage 3 or higher of New York Heart Association classification. 8.AST or ALT is 5 times higher or greater than normal values ,values differ among the hospitals 9.Alpha1 antitrypsin deficiency,Wilson's disease,primary biliary cirrhosis(PBC),or serum creatinine is twice higher than normal values 10.Ascites, encephalopathia 11.Possible labile hypertension or instability lipid abnormality found twelve weeks before obtaining informed consent 12.Alcohol or drug addiction 13.Pregnant, breast feeding, or possible pregnancy 14.Anyone who falls into contraindicated conditions 15.Any condition that may raise doctor concern
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of fat amount and means in the liver at 52 weeks from baseline measured with computer technology
- Secondary Outcome Measures
Name Time Method